Results 41 to 50 of about 2,182,415 (399)
Vaccines, Vaccination, and Vaccinology [PDF]
The Journal of Infectious Diseases, 2003 Although the demonstration in 1796 by Edward Jenner that vaccinia virus could protect against smallpox was epochal, he was following the path opened by the ancients who had used the smallpox virus itself in the practice of variolation. The work of Louis Pasteur on chicken cholera opened the way to vaccine development in the laboratory.
openaire +2 more sources
Barriers and facilitators to HPV vaccination in primary care practices: A mixed methods study using the Consolidated Framework for Implementation Research [PDF]
, 2018 Background In the United States, the effective, safe huma papilloma virus (HPV) vaccine is underused and opportunities to prevent cancer continue to be missed.
Dodd, Sherry +5 more
core +2 more sources
Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement [PDF]
, 2020 Introduction: The human papillomavirus (HPV) vaccine is recommended by the U.S. Centers for Disease Control and Prevention for routine vaccination of boys and girls to protect against HPV-related cancers and genital warts. To meet the Healthy People 2020
Baum, George P +8 more
core +2 more sources
Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production
Research, 2020 The generation of stable clones for biomolecule production is a common but lengthy and labor-intensive process. For complex molecules, such as viruses or virus-like particles (VLPs), the timeline becomes even more cumbersome. Thus, in the early stages of
Daniel J. Blackstock +7 more
doaj +1 more source
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]
, 2019 Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I. +5 more
core +1 more source
Human Vaccines & Immunotherapeutics, 2017 A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a ...
Christopher A. Seid +15 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia ...
Jeroen Pollet +19 more
doaj +1 more source
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
New England Journal of Medicine, 2021 Background Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making.
A. Jara +14 more
semanticscholar +1 more source
Evaluation of Microparticulate Ovarian Cancer Vaccine via Transdermal Route of Delivery [PDF]
, 2016 Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic approach with a promising antigenic delivery system ...
Akalkotkar, Archana +3 more
core +2 more sources
Overview of vaccines and vaccination [PDF]
Molecular Biotechnology, 2005 Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and ...
openaire +3 more sources